Some cases of specific cutaneous manifestations of acute myelogenous leukemia (AML) may mimic inflammatory dermatoses both clinically and histopathologically, presenting with an inconspicuous maculopapular eruption and with only sparse dermal infiltrates. The authors studied the histopathological and immunohistochemical features of 17 biopsies from 16 patients (11 men and 5 women, age range 15-85 years) presenting with minimal skin infiltrates as the first manifestation of AML or as first sign of recurrence after complete remission of the disease. In all cases, the diagnosis of leukemia has been confirmed by bone marrow examination. Two of these cases had been sent to one of us for second expert consultation. Patients presented with generalized, exanthematic maculopapular eruptions, sometimes with a hemorrhagic note, that were mostly interpreted clinically as drug reactions. Histopathologically, the lesions showed sparse, superficial, and mid-dermal infiltrates with minimal perivascular and periadnexal accentuation. Infiltrating cells consisted mostly of neoplastic monocytoid elements with only few reactive lymphocytes and histiocytes. Immunohistochemical stainings revealed in the majority of cases positivity for CD68 (14 of 16 patients), naphthol chloroacetate esterase (NaSDCl) (7 of 10 patients), and myeloperoxidase (6 of 9 patients). Other markers tested were positive only in a minority of cases. These cases represent a pitfall both in the clinical and in the histopathological diagnosis of cutaneous AML. Accurate morphologic and phenotypic correlation together with a high index of suspicion allows a precise diagnosis in these unconventional cases.
INTRODUCTION
Specific cutaneous infiltrates in patients with acute myelogenous leukemia (AML) show variable clinical and histopathological features, [1] [2] [3] [4] sometimes deviating from the conventional presentation characterized by generalized papules, plaques, and nodules with histopathologically nodular/ diffuse infiltrates. 5, 6 Relatively mild dermal infiltrates of myelogenous cells have been observed in 11.6% of cases in a recent study. 7 Accurate identification of these cases is important for planning management, especially when skin lesions precede the onset of leukemia or when they represent the first sign of relapse after complete remission (CR). 8, 9 Cases with minimal infiltrates may be mistaken for inflammatory dermatoses and represent a pitfall in the histopathological diagnosis of cutaneous manifestations of AML.
We studied histopathological and immunohistochemical features of specific cutaneous manifestations of AML with inconspicuous infiltrates, to identify diagnostic criteria in these difficult cases.
MATERIALS AND METHODS
The study has been conducted at the Research Unit Dermatopathology, Department of Dermatology, Medical University of Graz, Austria, and has been approved by the Ethic Committee of the University. Files were searched for skin specimens with diagnosis of cutaneous manifestations of AML from 1972 to June 2011. Cases presenting with histopathological features characterized by sparse infiltrates resembling inflammatory dermatoses were included in the study. In all cases, the diagnosis of leukemia had been confirmed by bone marrow examination. Cases characterized histopathologically by "conventional" nodular/diffuse infiltrates were excluded from the study. From a total of 108 cases of specific cutaneous manifestations of AML, 16 met the criteria and were included in the study. Two of these cases (cases 5 and 13) had been sent to L.C. for second expert consultation. Details of another case (case 8) have been published previously. 10 
Histopathological and Immunohistochemical Studies
A total of 17 biopsy specimens from the 16 patients were available for examination. Specimens were stained with hematoxylin and eosin and naphthol AS-D chloroacetate esterase (NaSDCl). All specimens were examined independently by 3 dermatopathologists (M.M.E., D.Z., and L.C.).
In cases with sufficient material, immunohistochemical studies using a panel of antibodies for myelogenous and lymphatic cells were performed (Table 1). A previously described standard 3-step immunoperoxidase technique with microwave enhancement was applied according to the manufacturer's protocol. 11 Tonsil tissue and normal skin structures served as external and internal controls, respectively. For negative controls, the primary antibody was omitted and replaced with normal human serum.
RESULTS

Clinical Data
Clinical data with a summary of provided clinical diagnoses are summarized in Table 1 . There were 11 men and 5 women (M/F ratio = 2.2:1). The age ranged from 15 to 89 years (mean 56.9 years, median 60.5 years).
Most patients presented with inconspicuous exanthematic macules and papules, sometimes with hemorrhagic aspect (Figs. 1 and 2, patients 2 and 16). The most common clinical diagnosis was drug reaction. A history of AML in CR was present in 6 patients. In 3 cases, only (all of them with a history of AML) a clinical differential diagnosis of cutaneous manifestations of AML was provided.
Follow-up data are summarized in Table 1 . All patients developed systemic signs of myelogenous leukemia within 0-18 months after skin biopsy. Six patients died of leukemia (range, 1-32 months); 10 patients are alive with leukemia (range, 1-25 months).
Histopathological Findings
One biopsy was taken in 14 patients; in the last case (case 8), 2 biopsies from different lesions were taken at the same time. Histopathologically, lesions showed sparse, superficial, and mid-dermal infiltrates with minimal perivascular and periadnexal accentuation (Figs. 3A, B, and 4A, B, patients 1 and 16, respectively) and with only occasional single array of cells between collagen bundles (Figs. 5A-C, patient 12) . The epidermis and the subcutaneous tissues were not involved. The cytomorphology consisted mainly of medium-sized blastoid monocytoid cells with a characteristic eosinophilic cytoplasm and round-oval, slightly lobulated nuclei with finely dispersed chromatin. In some cases, the cells displayed small but distinct nucleoli. Variable amounts of inflammatory cells were present in most cases but never represented the prominent cell population.
Histochemical and Immunohistochemical Findings
Detailed results are presented in Table 1 . Neoplastic cells in the majority of cases were positive for the 3 markers: CD68 (14 of 16 cases, 87.5%) ( Fig. 4C, patient 16 ), naphthol chloroacetate esterase (NaSDCl) (7 of 10 cases, 70%), and myeloperoxidase (MPO) (6 of 9 cases, 66.7%) ( Fig. 6, patient 13 ). Other markers were positive only in a minority of cases: CD33 in 5 of 13 cases (38.5%), CD56 in 4 of 12 cases (33.3%), CD34 in 3 of 11 cases (27.3%), CD117 in 1 of 11 cases (9.1%), CD123 in 1 of 12 cases (8.3%), and CD13 in 1 of 14 cases (7.1%). No positive cells were noted in the 12 cases tested for CD15. Stainings for T-cell markers (not reported in table) revealed only a few positive cells in a minority of cases ( Fig. 7, patient 16 ).
DISCUSSION
We presented 16 patients with sparse dermal infiltrates as specific cutaneous manifestations of AML. These cases represent a pitfall in the histopathological diagnosis, as they could be misinterpreted as an inflammatory skin disorder. In fact, 2 of these cases were sent for second expert consultation; in a third patient in CR after bone marrow transplantation for AML, the diagnosis of recurrent AML had been initially missed at another institution and had been made only upon review of the slides requested by the hematologists in charge of the patient (patient 7). Most of the cases were not initially suspected to be related to AML, and a history of AML in CR was present only in 6 patients. Provisional clinical diagnoses included drug eruption, Sweet syndrome, and leukocytoclastic vasculitis among others; only in 3 cases, specific infiltrate of AML was mentioned as a differential diagnosis. Typical histopathological changes of cutaneous AML such as dense diffuse infiltrates with perivascular and periadnexal accentuation of tumor cells were absent.
Although clinicopathologic features of specific cutaneous manifestations of AML usually allow a precise diagnosis, clinical manifestations mimicking benign skin conditions have been described. 2, 8, [12] [13] [14] Accurate diagnosis therefore relies on a high index of suspicion together with the ability to recognize the cytomorphologic features of tumor cells. 3, 7 In this context, unlike conventional dermatoses, specific infiltrates of AML, even when sparse, are characterized by a predominance of myelomonocytic cells with only small numbers of lymphocytes. Immunohistochemistry is crucial in order to correctly classify these cases. Previous studies have shown that CD68, lysozyme, and CD33 have very good sensitivity, being positive in .90% of cutaneous AML cases. 5, 7 MPO, CD4, and CD163 were positive in 50%-70% of cases; CD117, CD56, and CD14 in 30%-40% of cases; and CD34, CD56, CD123, and CD303 in ,20% of cases. 5, 7, 15 These findings are comparable to those observed in our study, showing CD68 and MPO positivity in 87% and 67% of cases, respectively. In addition, we could demonstrate that staining for NaSDCl is also a sensitive marker, being positive in 70% of cases. A lower percentage of MPO+ cases (42%) was found by Cronin et al 16 CD68 is a marker of monocytic/histiocytic lineage, and it is not surprising for AML to be consistently immunoreactive to it. 17 CD68 was considered as the most sensitive immunohistochemical marker for the detection of myeloid leukemia cutis regardless of FAB subtype. 5 Absence of CD68 staining in cutaneous manifestations of AML is rare and should prompt to consider also alternative diagnoses. Positivity for CD68 is useful in differentiating AML from drug reactions, as only a minority of cells (,20%) is positive for CD68 in skin specimens of this last condition. 18 This is in contrast to the positivity seen in most cases of AML, where the vast majority of infiltrating cells express CD68.
In the study by Cronin et al, 16 CD56 was positive in 47% of cases, not very dissimilar from the percentage observed in our study (33.3%). Although CD56 positivity is observed only in a minority of cases, these should not be misinterpreted as other CD56+ hematologic neoplasms such as blastic plasmacytoid dendritic cell neoplasm (BPDCN). 19 Because CD4 is usually positive both in AML and BPDCN, and because CD68 can be expressed by BPDCN, differentiation of the 2 entities relies on a wide panel of antibodies including myelomonocytic markers, TCL-1, BDCA-2, and CD123. 19 Cutaneous AML infiltrates may arise within pre-existing inflammatory or neoplastic skin conditions, posing further diagnostic problems. One of our patients (case 8, previously reported by Metzler et al 10 ) had a history of psoriasis and developed AML with specific manifestations of the disease within the psoriatic plaques. Histopathological examination showed large atypical mononuclear cells in the upper dermis along with typical findings of psoriasis. The cells were positive for MPO, NaSDCl, CD68, CD74, CD43, and lysozyme. Similarly, Diaz-Cascajo and Bloedern-Schlicht 20 reported a case of a basal cell carcinoma in association with a dense myeloblastic infiltrate in a patient with chronic myelogenous leukemia. It was postulated that circulating blast cells were attracted to neoplastic or inflammatory lesions in response to antigenic stimuli. One of the most important differential diagnoses of cutaneous specific manifestations of AML is with Sweet syndrome. One study revealed CD68 and MPO positivity in 6 of 11 cases of conventional Sweet syndrome with co-expression of the 2 markers in all cases. 21 Intense immunoreactivity was especially seen in the histiocytoid variant of Sweet syndrome. 22 It was postulated that immature myeloid cells were released by the bone marrow in early acute stages of the disease in this condition, thus accounting for the peculiar histologic and phenotypic features. On the other hand, the presence of specific cells of AML has been described within lesions of Sweet syndrome, 23 thus complicating the diagnosis in such cases. However, Sweet syndrome presents histopathologically with dense superficial and mid-dermal neutrophilic infiltrates accompanied by moderate to intense papillary dermal edema, in contrast with the minimal inflammatory infiltrate seen in the patients with AML described in this study.
In summary, we presented a group of patients with minimal cutaneous infiltrates of AML, representing a pitfall in the histopathological diagnosis. Accurate morphologic and phenotypic correlation together with a high index of suspicion allows a precise diagnosis in these unconventional cases.
